{
    "clinical_study": {
        "@rank": "142854", 
        "arm_group": [
            {
                "arm_group_label": "Dose level 1", 
                "arm_group_type": "Experimental", 
                "description": "Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group."
            }, 
            {
                "arm_group_label": "Dose level 2", 
                "arm_group_type": "Experimental", 
                "description": "Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group."
            }, 
            {
                "arm_group_label": "Dose level 3", 
                "arm_group_type": "Experimental", 
                "description": "Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group."
            }, 
            {
                "arm_group_label": "Dose level 4", 
                "arm_group_type": "Experimental", 
                "description": "Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group."
            }, 
            {
                "arm_group_label": "Dose level 5", 
                "arm_group_type": "Experimental", 
                "description": "Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group."
            }, 
            {
                "arm_group_label": "Dose level 6", 
                "arm_group_type": "Experimental", 
                "description": "Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group."
            }, 
            {
                "arm_group_label": "Dose level 7", 
                "arm_group_type": "Experimental", 
                "description": "Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group."
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of this first human dose trial is to investigate\n      the safety, tolerability, pharmacodynamic (the effect of the investigated drug on the body)\n      and pharmacokinetic (exposure of the trial drug in the body) properties of NNC0148-0000-0287\n      (insulin 287) in a GIPET\u00ae I tablet formulation in healthy subjects."
        }, 
        "brief_title": "A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body mass index 18.0-28.0 kg/m^2\n\n          -  Subject who is considered to be healthy based on the medical history, physical\n             examination, and the results of vital signs, electrocardiogram (ECG) and clinical\n             laboratory tests performed during the screening visit, as judged by the investigator\n\n        Exclusion Criteria:\n\n          -  Known or suspected hypersensitivity to trial products or related products\n\n          -  Previous participation in this trial. Participation is defined as randomised\n\n          -  Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea,\n             vomiting, heartburn or diarrhoea) within 2 weeks prior to dosing, as judged by the\n             investigator\n\n          -  Any chronic disorder or severe disease which, in the opinion of the investigator,\n             might jeopardise subject's safety or compliance with the protocol"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "84", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01809184", 
            "org_study_id": "NN1956-4014", 
            "secondary_id": [
                "2012-003048-66", 
                "U1111-1132-1018"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Dose level 1", 
                    "Dose level 2", 
                    "Dose level 3", 
                    "Dose level 4", 
                    "Dose level 5", 
                    "Dose level 6", 
                    "Dose level 7"
                ], 
                "description": "Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp.", 
                "intervention_name": "insulin 287", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Dose level 1", 
                    "Dose level 2", 
                    "Dose level 3", 
                    "Dose level 4", 
                    "Dose level 5", 
                    "Dose level 6", 
                    "Dose level 7"
                ], 
                "description": "Insulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels.", 
                "intervention_name": "insulin glargine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Dose level 1", 
                    "Dose level 2", 
                    "Dose level 3", 
                    "Dose level 4", 
                    "Dose level 5", 
                    "Dose level 6", 
                    "Dose level 7"
                ], 
                "description": "Oral placebo adminstered corresponding to insulin 287 treatment", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Insulin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 7, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany", 
                    "zip": "41460"
                }
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "7", 
        "official_title": "A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Charlotte Adrian", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of adverse events (AEs)", 
            "safety_issue": "No", 
            "time_frame": "As recorded from trial product administration and until completion of Sub-visit 2G (Day 13)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01809184"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the serum insulin concentration-time curve", 
                "safety_issue": "No", 
                "time_frame": "From 0 to 648 hours after a single dose"
            }, 
            {
                "measure": "Area under the glucose infusion rate (GIR)-time curve", 
                "safety_issue": "No", 
                "time_frame": "From 0 to 24 hours after a single dose"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}